Breaking Finance News

Abaxis (NASDAQ:ABAX) has been downgraded from Buy to Neutral in a statement by Northcoast earlier today.

Northcoast has downgraded Abaxis (NASDAQ:ABAX) from Buy to Neutral in a statement released on 11/30/2016.

On Thursday February 04, 2016, Credit Suisse released a statement for Abaxis (NASDAQ:ABAX) bumped up the target price from $0.00 to $39.00 that suggested a downside of -0.05%.

Boasting a price of $52.21, Abaxis (NASDAQ:ABAX) traded -1.19% lower on the day. With the last stock price close up 4.82% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same time. The company has recorded a 50-day moving average of $50.70 and a 200-day moving average of $49.22. 225,308 shares of the stock were exchanged, up from an average trading volume of 141,056

See Chart Below

Abaxis (NASDAQ:ABAX)

Abaxis has a 52 week low of $37.71 and a 52 week high of $58.15 with a P/E ratio of 33.46 The company’s market cap is currently $0.

In addition to Northcoast reporting its target price, a total of 6 brokerages have issued a ratings update on Abaxis. The 12-month price target is $53.42 with two brokerages rating the company a strong buy, zero brokerages rating the company a buy, six brokerages rating the company a hold, one brokerage rating the company a underperform, and lastly zero brokerages rating the company a sell.

General Company Details For Abaxis (NASDAQ:ABAX)

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company's segments are the medical market and the veterinary market. The Company's medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company's veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *